Fibrocell Science (NASDAQ: FCSC) and Organovo (NASDAQ:ONVO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.
This is a summary of recent ratings and recommmendations for Fibrocell Science and Organovo, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fibrocell Science presently has a consensus target price of $6.50, suggesting a potential upside of 1,040.35%. Organovo has a consensus target price of $3.94, suggesting a potential upside of 267.99%. Given Fibrocell Science’s stronger consensus rating and higher probable upside, analysts clearly believe Fibrocell Science is more favorable than Organovo.
Earnings & Valuation
This table compares Fibrocell Science and Organovo’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fibrocell Science||$350,000.00||42.18||-$15.29 million||($1.82)||-0.31|
|Organovo||$4.23 million||28.04||-$38.44 million||($0.36)||-2.97|
Fibrocell Science has higher earnings, but lower revenue than Organovo. Organovo is trading at a lower price-to-earnings ratio than Fibrocell Science, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
48.8% of Fibrocell Science shares are held by institutional investors. Comparatively, 27.3% of Organovo shares are held by institutional investors. 2.1% of Fibrocell Science shares are held by insiders. Comparatively, 10.2% of Organovo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Fibrocell Science has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Organovo has a beta of 2.76, suggesting that its share price is 176% more volatile than the S&P 500.
This table compares Fibrocell Science and Organovo’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About Fibrocell Science
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.